40b92a76-f324-4cdd-8209-517d021acd47
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- COAGULATION+0.400
- MYOGENESIS+0.400
- NOTCH_SIGNALING+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- APICAL_JUNCTION+0.300
- HEDGEHOG_SIGNALING+0.300
- HYPOXIA+0.300
Top 10 suppressed
- PROTEIN_SECRETION-0.500
- INTERFERON_ALPHA_RESPONSE-0.400
- ANDROGEN_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- ALLOGRAFT_REJECTION-0.200
- G2M_CHECKPOINT-0.200
- MITOTIC_SPINDLE-0.200
- MYC_TARGETS_V1-0.200
- UV_RESPONSE_DN-0.200
- E2F_TARGETS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.867 |
| 2 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.858 |
| 3 | a8235ad1-0c5f-4a0b-b595-85ef3a1e49ff | — | — | 0.855 |
| 4 | 09f758e5-6be1-4f29-ac92-869d92f8fbcf | — | — | 0.849 |
| 5 | SAMN03290888 | — | — | 0.843 |
| 6 | 44f9e45d-d779-4865-8f10-d085d5d25447 | — | — | 0.841 |
| 7 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.840 |
| 8 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.827 |
| 9 | BS_196BBNEJ | Posterior Fossa Ependymoma | — | 0.823 |
| 10 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |